{{Infobox company
| name = 瑞颂制药<br>Alexion Pharmaceuticals
| logo = [[File:Alexion_Pharmaceuticals_logo.svg|275px]]
| type = 子公司
| traded_as = 在纳斯达克上市时为：ALXN
| founded = {{start date and age|1992}}
| founder = Leonard Bell
| location_city = {{USA}}[[康涅狄格州|康涅狄格州]][[柴郡_(康涅狄格州)|柴郡]]
| key_people = Max E. Link <small>董事長</small><br>David L. Hallal <small>CEO</small>
| industry = [[製藥|製藥]]
| products = [[Eculizumab|Soliris]] 
| revenue = {{nowrap|{{increase}} 60.69亿美元 (2020年)}}
| net_income = {{nowrap|{{decrease}} 6.03亿美元 (2020年)}}
| assets = {{nowrap|{{increase}} 181.03亿美元 (2020年)}}
| equity = {{nowrap|{{increase}} 16.51亿美元 (2020年)}}
| num_employees = 2,525 (2020年)
| parent = [[阿斯利康|阿斯利康]] 
| homepage = {{URL|https://www.alexion.com}}
}}

'''瑞颂制药'''（{{Lang-en|Alexion Pharmaceuticals Inc.}}），也譯為'''亚力兄制药'''，是一家美國製藥公司，以發明治療[[非典型溶血尿毒綜合症|非典型溶血尿毒綜合症]]及[[陣發性夜間血紅素尿症|陣發性夜間血紅素尿症]]的藥物[[Eculizumab|Soliris]]而出名，<ref>{{cite web|url=http://www.medicalnewstoday.com/articles/221849.php|title=Alexion Submits Application for Soliris|date=2011-04-08}}</ref><ref name=Forbes>{{cite web|url=http://www.forbes.com/companies/alexion-pharmaceuticals/|title=Alexion Pharmaceuticals on the Forbes World’s Most Innovative Companies List|work=forbes.com|accessdate=2012-09-28|archive-date=2021-02-01|archive-url=https://web.archive.org/web/20210201075850/https://www.forbes.com/companies/alexion-pharmaceuticals/|dead-url=no}}</ref>此外也開發其他針對免疫系統疾病的藥物。<ref name=Everything>{{cite news|title=Everything you need to know about the $8.4B acquisition of Synageva|author=Don Seiffert|work=Boston Business Journal|date=2015-05-06|url=http://www.bizjournals.com/boston/blog/bioflash/2015/05/everything-you-need-to-know-about-the-8-4b.html|accessdate=2015-05-08|archive-date=2020-11-08|archive-url=https://web.archive.org/web/20201108165910/https://www.bizjournals.com/boston/blog/bioflash/2015/05/everything-you-need-to-know-about-the-8-4b.html|dead-url=no}}</ref>

==历史==
1992年由倫納德·貝爾（Leonard Bell）創立，1996年在[[纳斯达克|纳斯达克]]挂牌上市。2021年7月被[[阿斯利康|阿斯利康]]以390億美元（133億美元現金加2.36億股阿斯利康股票）收购，从[[纳斯达克|纳斯达克]]除牌退市。<ref>{{Cite news | url=https://www.fiercepharma.com/pharma/astrazeneca-closes-mega-39b-alexion-buyout-despite-antitrust-fears-making-a-splash-rare | title=AstraZeneca closes mega $39B Alexion buyout despite antitrust fears, making a splash in rare diseases | first=Noah | last=Higgins-Dunn | work=[[FiercePharma|FiercePharma]] | date=2021-07-21}}</ref><ref>{{Cite press release | url=https://www.astrazeneca.com/media-centre/press-releases/2021/acquisition-of-alexion-completed.html | title=Acquisition of Alexion completed | publisher=[[AstraZeneca|AstraZeneca]] | date=2021-07-21}}</ref>

==參考文獻==
{{Reflist}}

==外部連結==
* {{Official website|https://www.alexion.com}}

{{阿斯利康制药}}
{{Authority control}}
[[Category:阿斯利康制药|Category:阿斯利康制药]]
[[Category:美國製藥公司|Category:美國製藥公司]]
[[Category:波士顿公司|Category:波士顿公司]]
[[Category:罕用药公司|Category:罕用药公司]]
[[Category:納斯達克已除牌公司|Category:納斯達克已除牌公司]]
[[Category:1992年成立的公司|Category:1992年成立的公司]]
[[Category:1996年首次公開募股|Category:1996年首次公開募股]]
{{DEFAULTSORT:Alexion}}